Microbot Medical (MBOT) EBITDA Margin (2010 - 2026)

Microbot Medical's (MBOT) quarterly EBITDA Margin came in at 4114.29% in Q1 2026, down 2903.13% on a QoQ basis from 137.0% in Q1 2017.

Microbot Medical (MBOT) EBITDA Margin (2010 - 2026) Analysis & Trends

Microbot Medical (MBOT) has 9 years of EBITDA Margin data on file, last reported at 4114.29% in Q1 2026.

Quarterly EBITDA Margin changed N/A year-over-year to 4114.29% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1376.38% (changed N/A YoY) and the FY2017 annual result came in at 2942.46%, up 746593.0% from the prior year.
EBITDA Margin retreated to 4114.29% in Q1 2026, from 137.0% in the prior quarter.
In the past five years, EBITDA Margin ranged from a high of 4114.29% in Q1 2026 to a low of 4114.29% in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Intuitive Surgical	134.94 Bn	129.72 Bn	1.96 Bn	33.60%
2	Becton Dickinson	52.48 Bn	51.62 Bn	2.32 Bn	13.31%
3	Alcon	35.77 Bn	34.41 Bn	1.68 Bn	0.39%
4	Resmed	33.95 Bn	32.49 Bn	861.22 Mn	30.66%
5	Medline	29.32 Bn	26.65 Bn	2.22 Bn	5.14%
6	West Pharmaceutical Services	24.94 Bn	24.51 Bn	329.20 Mn	20.53%
7	Solventum	15.32 Bn	14.92 Bn	1.29 Bn	8.19%
8	Cooper Companies	14.87 Bn	14.73 Bn	735.40 Mn	-2.87%
9	Baxter International	13.61 Bn	11.46 Bn	1.03 Bn	7.33%
10	Microbot Medical	102.02 Mn	102.02 Mn	2,000.00	-4,114.29%

Download Data